CACáceres Méndez Edward Andres

Cáceres Méndez Edward Andres

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cáceres Méndez Edward Andres has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When Myocardial Injury in Lupus Is Not Lupus: Probable Antimalarial‐Associated Cardiomyopathy Mimicking Lupus Myocarditis

    by Diego Armando Pérez Covo, María Camila Bernal Beltrán, Diego Alejandro Ortega, Cristian Orlando Porras Bueno, Emilio José Juan Guardela, Carlos Hernán Calderón, Edward Andres Cáceres Méndez, Laura Valentina Omaña Álvarez, Alejandro Mariño Correa, Ángel Alberto García Peña

    Antimalarial cardiotoxicity may mimic lupus myocarditis in systemic lupus erythematosus. We report a 53‐year‐old woman with chronic antimalarial exposure, myocardial injury, biventricular dysfunction, electrical abnormalities, low lupus activity, and no myocardial edema. Chloroquine withdrawal was followed by clinical improvement and left ventricular function recovery, supporting probable antimalarial‐associated cardiomyopathy.


  • Open Access

    Utility of the Triglyceride and HDL Cholesterol Index in Older Persons in Colombia

    by Carolina Murgueitio Guzmán, Jesús Andrés Beltrán España, Ángel Alberto García Peña, Edward Cáceres, Cándida Díaz‐Brochero, Miguel Ángel Narváez Chaves, Luciano Villa Miranda

    Background: Alterations in lipid metabolism are key contributors to the development of atherogenesis and the increasing prevalence of atherosclerotic cardiovascular diseases, including coronary artery disease, peripheral arterial disease, and cerebrovascular disease. The triglyceride‐to‐HDL cholesterol (TG/HDL‐c) index is commonly used to assess cardiovascular disease risk; however, its effectiveness in older adults remains unclear. Methods: This study evaluated the association and predictive capacity of the TG/HDL‐c index for cardiometabolic risk factors in older adults from the SABE Colombian study. A cross‐sectional analysis was performed among adults aged ≥ 60 years from the national SABE survey. Univariable and multivariable logistic regression models were constructed to examine associations between the TG/HDL‐c index and diabetes or metabolic syndrome, adjusting for age, sex, BMI, smoking, diet, and physical activity. Discriminatory capacity was assessed using receiver operating characteristic curves, and optimal cut‐off points were determined using the Youden index. Results: A total of 23,694 participants with a median age of 69 years were included; 57.3% were women. The TG/HDL‐c index was independently associated with both diabetes (adjusted OR per 1 SD: 1.25; 95% CI: 1.13–1.37; p < 0.001) and metabolic syndrome (adjusted OR per 1 SD: 2.82; 95% CI: 2.46–3.22; p < 0.001). The index demonstrated a good discriminatory performance for diabetes (AUC = 0.89; 95% CI: 0.86–0.93; cut‐off = 9.17; sensitivity = 0.81; specificity = 0.90) and metabolic syndrome (AUC = 0.86; 95% CI: 0.85–0.88; cut‐off = 8.81; sensitivity = 0.71; specificity = 0.92). In contrast, discriminatory performance was limited for hypertension, prediabetes, cardiovascular disease, and cerebrovascular disease (AUC range 0.52–0.67). Conclusions: The TG/HDL‐c index was independently associated with diabetes and metabolic syndrome and demonstrated good discriminatory performance in this nationally representative sample of older adults. Although these results highlight its potential utility for identifying individuals at higher cardiometabolic risk, further longitudinal studies are needed to validate these findings and determine the prognostic value of TG/HDL‐c for clinical decision‐making in elderly populations.

  • Performance of the LEVO-D score in patients with advanced heart failure at a referral hospital

    by Mauricio Manrique-Samer, Nicolás Rodríguez Medina, Alejandro Mariño, Edward Cáceres Mendez, Ángel Alberto García

    Advanced heart failure is a prevalent and burdensome condition, and effective therapies are needed. Ambulatory intermittent levosimendan infusion has been used to reduce cardiovascular events, although response rates vary. This study assessed the LEVO-D score as a predictive tool in patients receiving levosimendan infusions under standardised conditions. We conducted a prospective observational study at the Heart Failure Clinic of a tertiary-level teaching hospital between September 2020 and March 2024. A total of 67 patients received a median of 10 intermittent levosimendan infusions and were followed for a mean duration of 18 months. The performance of the LEVO-D score was assessed using receiver operating characteristic (ROC) curve analysis and descriptive statistics. The patients were elderly, with a mean age of 69.5 years, a high comorbidity burden, and an advanced functional class. All patients received beta-blockers, and most had a high rate of guideline-directed therapy. At 18 months, the mortality rate was 36.2% and the hospitalisation rate was 42%. The LEVO-D score showed good predictive value for hospitalisation (AUC 0.81), moderate predictive value for clinical response (AUC 0.64), and poor predictive value for mortality (AUC 0.58). A cut-off value of ≥1.0 provided the optimal balance between sensitivity and specificity for identifying responders. The LEVO-D score showed consistent discriminatory capacity in our cohort despite a high rate of optimal medical therapy and a low rate of edge-to-edge transcatheter repair, thus supporting its utility and encouraging further validation in diverse clinical settings.


  • Open Access

    An Unusual Case of 11αB ‐Crystallin ( CRYAB ) Mutation as a Cause of Dilated Cardiomyopathy With Restrictive Physiology: A Case Report and Focused Review of the Literature

    by Porras Bueno Cristian Orlando, Cruz Buitrago Roberto Hernando, Mariño Correa Alejandro, Cáceres Méndez Edward Andres, Eugenio Meek, Ríos Dueñas Edgar Giovanni

    Several diseases have been linked to αB‐crystallin (CRYAB) mutation. However, this mutation is an uncommon cause that has been associated in recent years with the development of dilated cardiomyopathy. We report a case of dilated cardiomyopathy with restrictive physiology due to a CRYAB mutation.